Sulfonylurea Management in Type 2 Diabetes

Key Differences and Clinical Considerations

Gliclazide MR demonstrates a significantly lower risk of hypoglycemia compared to older sulfonylureas, with newer-generation sulfonylureas like gliclazide MR and glimepiride showing superior safety profiles during fasting periods such as Ramadan 1
Glipizide carries a higher inherent risk of hypoglycemia, particularly in high-risk populations such as elderly patients and those with chronic kidney disease 2, 3
Both agents lack the cardiovascular benefits seen with newer agents like SGLT2 inhibitors and GLP-1 receptor agonists 2, 4
For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors or GLP-1 receptor agonists should be prioritized over any sulfonylurea due to proven cardiovascular and renal benefits 4, 5
Never use chlorpropamide during Ramadan or in elderly patients due to high risk of prolonged, unpredictable hypoglycemia 1
Metformin remains the first-line medication for type 2 diabetes management; sulfonylureas should be considered as second-line agents 2, 5
Monitor for hypoglycemia more carefully in patients with irregular meal patterns, increased physical activity, or alcohol consumption 1
Greatest caution with any sulfonylurea is warranted for older patients at high risk of hypoglycemia 2, 3
Both agents require caution in patients with chronic kidney disease due to increased hypoglycemia risk 2, 3